PMID: 8581368Oct 1, 1995Paper

A human Fc gamma RI/CD64 transgenic model for in vivo analysis of (bispecific) antibody therapeutics

Journal of Hematotherapy
I A Heijnen, J G van de Winkel

Abstract

The human high-affinity IgG receptor, hFc gamma RI (CD64), is exclusively expressed on myeloid cells, where it serves an important role as a (cytotoxic) trigger molecule. To establish an in vivo model for analysis of the role of hFc gamma RI in immunity, we developed a novel transgenic mouse model. The human Fc gamma RIA gene, with endogenous regulatory sequences, was used to generate two lines of transgenic FVB/N mice. Immunohistochemical and flow cytometric studies showed that hFc gamma RI expression was restricted to myeloid cells. Monocytes, macrophages, and polymorphonuclear neutrophils (PMN) expressed physiologic hFc gamma RI levels, whereas lymphocytes and mast cells lacked expression. Human Fc gamma RI expression was regulated in vivo by the cytokines IFN-gamma (exactly as in humans) and IL-10. The transgenic receptor proved functional and bound human tumor cells via anti-hFc gamma RI-based bispecific antibodies. hFc gamma RI could, furthermore, be efficiently targeted in vivo by CD64 antibodies. These data demonstrate that the hFc gamma RI transgenic mouse model closely parallels the situation in humans. This mouse model seems useful for in vivo evaluation of the therapeutic potential of novel bispecific reagents in tu...Continue Reading

References

Nov 1, 1991·Trends in Biotechnology·M W Fanger, P M Guyre
Apr 15, 1994·Journal of Immunological Methods·H F SavelkoulA van Oudenaren
Jun 1, 1994·Journal of Leukocyte Biology·P K WallaceM W Fanger
May 1, 1993·Immunology Today·J G van de Winkel, P J Capel

❮ Previous
Next ❯

Citations

Nov 5, 1998·International Journal of Clinical & Laboratory Research·M A Cassatella
Oct 2, 2001·Critical Reviews in Oncology/hematology·P M McLaughlinL F de Leij
Jul 2, 2004·Proceedings of the National Academy of Sciences of the United States of America·Jeffrey M BeekmanJeanette H W Leusen
Jan 18, 2006·British Journal of Haematology·Lisette BevaartTibor Keler
Apr 25, 2008·Current Protocols in Immunology·Malaya Bhattacharya-ChatterjeeSunil K Chatterjee
Oct 27, 2015·Immunological Reviews·Pierre Bruhns, Friederike Jönsson
Dec 20, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·T KelerR F Graziano
Nov 6, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Hongwei QinRobert P Kimberly

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.